Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aphylaxis - Overview
Aphylaxis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aphylaxis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aphylaxis - Companies Involved in Therapeutics Development
Aquestive Therapeutics Inc
ARS Pharmaceuticals Inc
Bryn Pharma LLC
G2B Pharma Inc
Great Bay Bio Holdings Ltd
Insys Therapeutics Inc
JDP Therapeutics Inc
MannKind Corp
Merck & Co Inc
Pharmacin BV
Shenox Pharmaceuticals LLC
Aphylaxis - Drug Profiles
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GBB-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLK-0006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmory Inflammation, Systemic Aphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmory Inflammation, Systemic Aphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHX-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aphylaxis - Dormant Projects
Aphylaxis - Product Development Milestones
Featured News & Press Releases
Oct 29, 2020: Insignis Therapeutics and HLK Pharmacin receive FDA IND clearance to initiate a phase 1 trial with IN-001 for oral aphylaxis treatment
Aug 20, 2020: Aquestive Therapeutics initiates Phase 1 Pharmacokinetic trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in development for treatment of allergic reactions including aphylaxis
Aug 10, 2020: Aquestive Therapeutics receives FDA Fast Track Desigtion for AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including aphylaxis
Jul 13, 2020: ARS Pharmaceuticals announces new patent on ARS-1 (epinephrine sal spray)
Jun 29, 2020: Aquestive Therapeutics files IND for pharmacokinetic clinical trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for aphylaxis treatment
Jun 10, 2020: Bryn Pharma announces the Publication of positive results from its Intrasal Epinephrine Preclinical Study program In three Peer-Reviewed Scientific Jourls
May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intrasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors
Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodymic effects of intrasal Epinephrine to intramuscular Epinephrine in adults
Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting
Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for aphylaxis treatment
Nov 10, 2019: Bryn Pharma Research on Epinephrine sal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting
Oct 29, 2019: Bryn Pharma presents data demonstrating patient preference for bi-dose epinephrine sal spray over EpiPen
Oct 10, 2019: Bryn Pharma completes dosing in pivotal clinical trial designed to support U.S. approval of Intrasal Epinephrine Spray
Sep 30, 2019: Aquestive Therapeutics Announces Successful Completion of Phase 1 Trial for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine)
Jun 04, 2019: ARS Pharmaceuticals announces results from EPI-04 clinical study of ARS-1 Intrasal Epinephrine Spray in Allergy Patients with Allergic Rhinitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Anaphylaxis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Top 10 Targets, H2 2020
Number of Products by Stage and Top 10 Targets, H2 2020
Number of Products by Top 10 Mechanism of Actions, H2 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
Number of Products by Top 10 Routes of Administration, H2 2020
Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Number of Products by Top 10 Molecule Types, H2 2020
Number of Products by Stage and Top 10 Molecule Types, H2 2020


List of Tables


Number of Products under Development for Anaphylaxis, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products under Development by Universities/Institutes, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Universities/Institutes, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, H2 2020
Anaphylaxis - Pipeline by Bryn Pharma LLC, H2 2020
Anaphylaxis - Pipeline by G2B Pharma Inc, H2 2020
Anaphylaxis - Pipeline by Great Bay Bio Holdings Ltd, H2 2020
Anaphylaxis - Pipeline by Insys Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by JDP Therapeutics Inc, H2 2020
Anaphylaxis - Pipeline by MannKind Corp, H2 2020
Anaphylaxis - Pipeline by Merck & Co Inc, H2 2020
Anaphylaxis - Pipeline by Pharmacin BV, H2 2020
Anaphylaxis - Pipeline by Shenox Pharmaceuticals LLC, H2 2020
Anaphylaxis - Dormant Projects, H2 2020